Subscribe

Institute of Biomedical Research Corp. (MRES)

USD0.00 +0.00 (+3.17%)
ME OTC Healthcare Biotechnology
Address Ljubljanska bb 81000
Podgorica, ME
CEO Drasko D. Pekovic
IPO 2004-07-29
ISIN US45781A1079

Explore sections of this company profile

Description

Institute of Biomedical Research Corp. (MRES) is a dedicated provider of comprehensive biomedical research and analytical services, operating both within Montenegro and across international markets. The company's core activities encompass fundamental scientific investigation and robust research and development initiatives for new biomedical products, advanced technologies, and innovative diagnostic methods, including experimental medical treatments. MRES also focuses on the creation of novel biomedical and food products. A significant part of its mandate involves regulatory oversight of industrial activities and their associated products, alongside scientific environmental monitoring. Furthermore, it delivers expert regulatory evaluation and certification services for a wide array of biomedical products. The institute also contributes to academic advancement through graduate research study programs in the biomedical and environmental fields. MRES manufactures and supplies a diverse range of healthcare devices. Its offerings include two-channel analog NMS units, various digital muscle stimulators, digital TENS devices, interferential therapy units, elite combination models, portable four-channel digital stimulators, and portable ultrasound equipment. The product portfolio also extends to photon red light devices for aesthetic applications, electric pain relief solutions, microcurrent electrical nerve stimulators, and high-volt pulsed stimulators. The company excels in the development and commercialization of specialized agents and products. This category features microbicidal agents, a variety of disinfectant solutions, and specialized medical supplies such as bandages tailored for severe burns. They also provide products for hard surface disinfection, microbicidal treatments for fabrics and textiles, insecticides (including those targeting bed bugs), microbicidal towels, and mouthwash. Key innovations include Purilair, an apparatus specifically designed for sterilizing compressed air within medical instruments, alongside colloidal silver and other electro-medical devices. A notable product is BioStim INF, which is engineered for reducing edema, alleviating pain, and delivering comprehensive therapeutic benefits. Beyond its product and research endeavors, MRES offers a broad spectrum of essential services. These include quality control, regulatory assistance, healthcare support, environmental analysis, building decontamination, and extensive environmental protection and management services. They are also a critical source for regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was established in 2010 and maintains its headquarters in Podgorica, Montenegro, with a representative office located in Montreal, Canada, facilitating its global operations.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+3.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.61
Float Shares
1.24B
Free Float %
45.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +30.77% +13.33% -10.53% -71.67% -39.29% -91.50% -80.00% +30.77% -78.75% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
DCF (Unlevered) 0.00 -61.9%
DCF (Levered) 0.00 -65.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-23.35
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • Revenue growth Biotechnology: +1.6%
    +9.8% Q4'25: -100.0% (vs Q4'24)
  • EPS growth Biotechnology: +29.7%
    -133.3% Q4'25: -100.0% (vs Q4'24)
  • FCF margin FCF growth · Biotechnology: +16.2%
    -1,494.6%
  • EBIT margin Biotechnology: +0.0%
    -1,463.5%
  • ROIC Biotechnology: -16.1%
    -28.7% Q4'25: -9.1% (vs Q4'24)
  • Share dilution Biotechnology: -3.4%
    +12.3% Q4'25: +14.0% (vs Q4'24)
  • Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q4'25: 0.00× (vs Q4'24)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.19) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Intrinsic value (base): 0.00 Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-01 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-1.0K
Shares Outstanding
2.70B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Drasko D. Pekovic Founder, Chairman of the Board, Chief Executive Officer & President
Teodor Burtea Director & Member of Scientific Council male
Victor Lange Chief Executive Officer of M2MMA male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits